VAN-RIZATRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

可用日期:

VANC PHARMACEUTICALS INC

ATC代码:

N02CC04

INN（国际名称）:

RIZATRIPTAN

剂量:

10MG

药物剂型:

TABLET (ORALLY DISINTEGRATING)

组成:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10MG

给药途径:

ORAL

每包单位数:

6

处方类型:

Prescription

治疗领域:

SELECTIVE SEROTONIN AGONISTS

產品總結:

Active ingredient group (AIG) number: 0137841002; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2019-08-07

产品特点

PRODUCT MONOGRAPH
PR
VAN-RIZATRIPTAN ODT
Rizatriptan Benzoate Orally Disintegrating Tablets
5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Vanc Pharmaceuticals Inc.
Date of Preparation:
210-2639, Viking way 9 November, 2015
Richmond, BC V6V3B7
www.vancpharm.com
Submission Control No: 188668
_ _
_VAN-Rizatriptan ODT _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
...............................................................................................................
18
DOSAGE AND ADMINISTRATION
...........................................................................................
20
OVERDOSAGE
.............................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
22
STORAGE AND STABILITY
......................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 26
PART II: SCIENTIFIC INFORMATION